GlassScriptPhysician profile
Maxim Pekarev
NPI 1851618649
$3,099.22
in general payments reported to CMS, 2019-2025
15 companies · $151 in 2025
The $151 reported for 2025 was less than what a typical Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $445).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $650 · 2020: $266 · 2021: $623 · 2022: $760 · 2023: $328 · 2024: $321 · 2025: $151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $799.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $782.68 | 2019-2025 | Renasys Touch, Collagenase Santyl, Stravix |
| Integra Lifesciences Corporation | $593.47 | 2019-2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Allergan, INC. | $456.46 | 2019-2022 | |
| Sientra, INC. | $365.25 | 2019-2022 | |
| Exsomed Corporation | $228.06 | 2021 | |
| Abbvie INC. | $170.02 | 2023 | |
| Acera Surgical, INC. | $128.57 | 2021 | |
| Merz North America, INC. | $122.84 | 2021-2022 | |
| Organogenesis INC. | $82.53 | 2024 | |
| Bone Support INC. | $39.05 | 2024 | Cerament G, Ceramentbone Void Filler |
| Axogen | $38.25 | 2019 | |
| Medline Industries LP | $38.14 | 2019 | |
| Galderma Laboratories, L.P. | $24.64 | 2019 | |
| Tela Bio, INC. | $16.23 | 2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Kci USA, INC. | $13.03 | 2023 | Prevena, V.A.C.Ulta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maxim Pekarev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.